CN102988325B - Preparation method of manidipine sustained release tablet - Google Patents
Preparation method of manidipine sustained release tablet Download PDFInfo
- Publication number
- CN102988325B CN102988325B CN201210377523.9A CN201210377523A CN102988325B CN 102988325 B CN102988325 B CN 102988325B CN 201210377523 A CN201210377523 A CN 201210377523A CN 102988325 B CN102988325 B CN 102988325B
- Authority
- CN
- China
- Prior art keywords
- manidipine
- sustained release
- release tablets
- carrageenan
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 229960003963 manidipine Drugs 0.000 title claims abstract description 65
- 239000007939 sustained release tablet Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 39
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000011248 coating agent Substances 0.000 claims abstract description 26
- 238000000576 coating method Methods 0.000 claims abstract description 26
- 239000000679 carrageenan Substances 0.000 claims abstract description 22
- 235000010418 carrageenan Nutrition 0.000 claims abstract description 22
- 229920001525 carrageenan Polymers 0.000 claims abstract description 22
- 229940113118 carrageenan Drugs 0.000 claims abstract description 22
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims abstract description 22
- 239000003826 tablet Substances 0.000 claims abstract description 17
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 13
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 13
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 13
- 230000001476 alcoholic effect Effects 0.000 claims description 16
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 239000011812 mixed powder Substances 0.000 claims description 8
- 239000007779 soft material Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000084 colloidal system Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 229940041476 lactose 100 mg Drugs 0.000 claims description 3
- 229940080428 lactose 200 mg Drugs 0.000 claims description 3
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229940085605 saccharin sodium Drugs 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 6
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 235000019658 bitter taste Nutrition 0.000 abstract description 5
- 238000005461 lubrication Methods 0.000 abstract 2
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000480 calcium channel blocker Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 102000003691 T-Type Calcium Channels Human genes 0.000 description 1
- 108090000030 T-Type Calcium Channels Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical group CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003684 cardiac depression Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- -1 filter immediately Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a manidipine sustained release tablet for treating hypertension, belonging to the technical field of a Western medicine preparation. The manidipine sustained release tablet consists of a tablet and a coating, and is characterized in that the tablet comprises the following components according to the total weight percentage of the sustained release tablet: 30-70 parts of manidipine, 10-30 parts of carrageenan, 1-10 parts of a lubrication glidant, 5-15 parts of citric acid and 1-20 parts of a sweetening agent; the coating comprises the following components in 100 parts by total weight of the sustained release tablet: 0.5-3 parts of sodium carboxymethylcellulose, 0.5-5 parts of propylene glycol and 0.5-2 parts of the lubrication glidant. The tablet provided by the invention has the advantages of slow release, small side effects on stomachs and intestines, and no bitter taste.
Description
Technical field
The invention belongs to Western medicine preparation technical field, particularly a kind of manidipine sustained release tablets for the treatment of senile dementia.
Background technology
Manidipine is a kind of lipophilic, third generation bihydropyridine type calcium channel blocker, CA registration number is 89226-75-5, molecular formula is C35H38N4O62HCl, molecular weight is 683.62, vascular smooth muscle is had to high selectivity, therefore can induce significantly peripheral vasodilation, and Cardiac depression effect is very slight.In addition, Manidipine can appreciable impact noradrenaline levels, shows that it can not affect sympathetic nervous system.After this drug administration, effect engenders but lastingly, can only take once every day.Manidipine can be exported and input tremulous pulse by diastole kidney, and kidney is had to certain benefit, and to the effect of kidney and its antihypertensive function uncorrelated.Every day, an oral Manidipine was to light effective and toleration is good to moderate hypertension patient.It should be noted that in a large-scale double blind, the patient of Manidipine group generation ankle edema will significantly be less than amlodipine group.Manidipine is also applicable to the hypertensive patient who has a complication, for example type 2 diabetes mellitus and renal function injury.Manidipine can improve insulin sensitivity and not affect metabolic function.In brief, Manidipine can be used as the line medication use that constitutional gently arrives moderate hypertension.
Manidipine is third generation calcium channel blocker, can suppress L-type and T-type calcium channel on smooth muscle cell, makes peripheral vasodilation, causes blood pressure drops.In calcium, the inhibitory action of stream engenders, is scrubbing still sustainable existence of after date effect.After patient takes medicine, effect can continue 24 hours.In recommended dose, Manidipine does not have the impact of clinical remarkable meaning on heart rate or cardiac electrophysiology parameter.The Manidipine of therapeutic dose also can not affect the level of norepinephrine.Manidipine is useful to hypertensive patient's kidney, has had the patient of renal function injury also can use Manidipine.In the clinical trial of participating in the hyperpietic by merging chronic renal insufficiency of 12 weeks by a definite date, patient significantly improves at (every day 10 or 20 milligrams) creatinine clearance rate after Manidipine treatment, and serum creatinine level significantly reduces.And nifedipine (every day 30 or 60 milligrams) does not have above-mentioned effect.
Oral easy absorption, blood drug level peak time 1～2 hour is 97% with albumen knot rate in blood plasma.T1/2 approximately 5 hours, owing to absorbing rapidly, easily causes hypotension.
In sum, study and develop a kind of slow release, gastrointestinal side-effect is little, without the manidipine sustained release tablets of bitterness, seem particularly urgent.
Summary of the invention
In order to overcome the deficiencies in the prior art, the present invention to adjuvant screening and process optimization, provides a kind of manidipine sustained release tablets by lot of experiments.This tablet slow release, gastrointestinal side-effect are little, and without bitterness, preparation technology is simple.
The object of the present invention is achieved like this:
A preparation method for manidipine sustained release tablets, is comprised of plain sheet and coating, by slow releasing tablet total weight percent, described plain sheet consists of the following composition: Manidipine 30-70 part, carrageenan 10-30 part, lubricated fluidizer 1-10 part, citric acid 5-15 part and sweeting agent 1-20 part; Described coating is 100 parts by slow releasing tablet gross weight and consists of the following composition: sodium carboxymethyl cellulose 0.5-3 part, propylene glycol 0.5-5 part, lubricated fluidizer 0.5-2 part.
Above-mentioned a kind of manidipine sustained release tablets, lubricated fluidizer is selected from one or more in magnesium stearate, silicon dioxide, Pulvis Talci.
Above-mentioned a kind of manidipine sustained release tablets, sweeting agent is selected from one or more in lactose, sucrose, glucose, xylitol, sorbitol, mannitol, steviosin, saccharin sodium, aspartame.
Above-mentioned a kind of manidipine sustained release tablets, the plain slice prescription of manidipine sustained release tablets is as follows: Manidipine 500mg, carrageenan 200mg, magnesium stearate 50mg, citric acid 100mg, lactose 200mg; The coated formula of manidipine sustained release tablets is as follows: sodium carboxymethyl cellulose 10.5mg, propylene glycol 20mg, Pulvis Talci 9.5mg.
Above-mentioned a kind of manidipine sustained release tablets, the plain slice prescription of manidipine sustained release tablets is as follows: Manidipine 500mg, carrageenan 300mg, magnesium stearate 20mg, citric acid 50mg, lactose 100mg; The coated formula of manidipine sustained release tablets is as follows: sodium carboxymethyl cellulose 9.5mg, propylene glycol 19mg, Pulvis Talci 15mg.
The preparation method of above-mentioned a kind of manidipine sustained release tablets, the method comprises the following steps: that (1) is dissolved in part carrageenan in alcoholic solution, is prepared into alcoholic solution; (2) Manidipine after sieving, remaining carrageenan, citric acid, sweeting agent are placed in to high efficient mixed comminutor and fully mix, add the alcoholic solution of above-mentioned carrageenan, fully mix, make soft material; (3) after above-mentioned soft material is dry, add lubricated fluidizer, obtain mixed powder, mixed powder all adds Mixers with Multi-direction Movement, uses swinging lozenge machine tabletting, makes plain sheet; (4) preparation of coating solution: will lubricate after fluidizer sieves and mix, and add in the alcoholic solution containing sodium carboxymethyl cellulose and propylene glycol, and use again colloid mill circular grinding after stirring by hand, and make coating solution; (5) plain sheet is joined in atresia coating pan, regulate intake, after plain sheet preheating, add above-mentioned coating solution to carry out coating; (6) by the slow releasing tablet packing making.
Compared with prior art, the manidipine sustained release tablets the present invention relates to has following useful technique effect:
(1) discharge steadily.Limit is within 1 hour, to discharge 25-45%, within 4 hours, discharges 60-85%, within 8 hours, discharges more than 80%.
(2) gastrointestinal side-effect is little, without bitterness, and carrageenan parcel Manidipine raw material for the present invention, the method can be covered Manidipine bitterness and reach beyond thought effect.
(3) preparation technology is simple.The manidipine sustained release tablets of the present invention's screening is applicable to industrialized great production.
Accompanying drawing explanation
Fig. 1 is the In Vitro Dissolution curve of the tablet prepared of embodiment 1 and Manidipine direct compression
The specific embodiment
Form is described in further detail foregoing of the present invention again by the following examples, but this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following example, all technology realizing based on foregoing of the present invention all belong to scope of the present invention.
Embodiment 1
The plain slice prescription that takes manidipine sustained release tablets is as follows: Manidipine 500mg, carrageenan 200mg, magnesium stearate 50mg, citric acid 100mg, lactose 200mg; The coated formula of manidipine sustained release tablets is as follows: sodium carboxymethyl cellulose 10.5mg, propylene glycol 20mg, Pulvis Talci 9.5mg.
Preparation technology:
(1) 100mg carrageenan is dissolved in alcoholic solution, is prepared into alcoholic solution; (2) Manidipine after sieving, remaining carrageenan, citric acid, lactose are placed in to high efficient mixed comminutor and fully mix, add the alcoholic solution of above-mentioned carrageenan, fully mix, make soft material; (3) after above-mentioned soft material is dry, add lubricated fluidizer, obtain mixed powder, mixed powder all adds Mixers with Multi-direction Movement, uses swinging lozenge machine tabletting, makes plain sheet; (4) preparation of coating solution: mix after Pulvis Talci is sieved, add in the alcoholic solution containing sodium carboxymethyl cellulose and propylene glycol, use again colloid mill circular grinding after stirring by hand, make coating solution; (5) plain sheet is joined in atresia coating pan, regulate intake, after plain sheet preheating, add above-mentioned coating solution to carry out coating; (6) by the slow releasing tablet packing making.
The plain slice prescription that takes manidipine sustained release tablets is as follows: Manidipine 500mg, carrageenan 300mg, magnesium stearate 20mg, citric acid 50mg, lactose 100mg; The coated formula of manidipine sustained release tablets is as follows: sodium carboxymethyl cellulose 9.5mg, propylene glycol 19mg, Pulvis Talci 15mg.
Preparation technology:
(1) 100mg carrageenan is dissolved in alcoholic solution, is prepared into alcoholic solution; (2) Manidipine after sieving, remaining carrageenan, citric acid, lactose are placed in to high efficient mixed comminutor and fully mix, add the alcoholic solution of above-mentioned carrageenan, fully mix, make soft material; (3) after above-mentioned soft material is dry, add lubricated fluidizer, obtain mixed powder, mixed powder all adds Mixers with Multi-direction Movement, uses swinging lozenge machine tabletting, makes plain sheet; (4) preparation of coating solution: mix after Pulvis Talci is sieved, add in the alcoholic solution containing sodium carboxymethyl cellulose and propylene glycol, use again colloid mill circular grinding after stirring by hand, make coating solution; (5) plain sheet is joined in atresia coating pan, regulate intake, after plain sheet preheating, add above-mentioned coating solution to carry out coating; (6) by the slow releasing tablet packing making.
The release research of embodiment 3 manidipine sustained release tablets
Tablet (seeing comparative example 1 in Fig. 1) prepared by the tablet (specification 50mg) of the embodiment of the present invention 1 preparation and Manidipine direct compression contrasts.
Dissolution test method: get respectively the tablet (specification 50mg) of embodiment 1 preparation and tablet (specification 50mg) prepared by Manidipine direct compression, according to drug release determination method (two appendix X D first methods of Chinese Pharmacopoeia version in 2010), take distilled water 900ml as solvent, Revolution Per Minute 50 turns, operation in accordance with the law, through 1, 4, 8 hours, get solution 10ml, through 0.8um filter membrane, filter immediately, and supplement in time 10ml solvent, it is appropriate that precision measures subsequent filtrate, with distilled water, be quantitatively diluted to the solution that approximately contains 16ug in every 1ml, according to spectrophotography (two appendix VIA of Chinese Pharmacopoeia version in 2000), wavelength place at 252nm measures trap.It is appropriate that another precision takes Manidipine reference substance, with distilled water, dissolves and be also quantitatively diluted to the solution that contains 15 μ g in every 1ml.Be measured in the same method trap, calculate the stripping quantity of every.Limit is within 1 hour, to discharge 25-45%, within 4 hours, discharges 60-85%, within 8 hours, discharges more than 80%.
Claims (5)
1. a manidipine sustained release tablets, is comprised of plain sheet and coating, it is characterized in that by slow releasing tablet gross weight be 100 parts, described plain sheet consists of the following composition: Manidipine 30-70 part, carrageenan 10-30 part, lubricated fluidizer 1-10 part, citric acid 5-15 part and sweeting agent 1-20 part; Described coating is 100 parts by slow releasing tablet gross weight and consists of the following composition: sodium carboxymethyl cellulose 0.5-3 part, propylene glycol 0.5-5 part, lubricated fluidizer 0.5-2 part, preparation process is as follows: (1) is dissolved in part carrageenan in alcoholic solution, is prepared into alcoholic solution; (2) Manidipine after sieving, remaining carrageenan, citric acid, sweeting agent are placed in to high efficient mixed comminutor and fully mix, add the alcoholic solution of above-mentioned carrageenan, fully mix, make soft material; (3) after above-mentioned soft material is dry, add lubricated fluidizer, obtain mixed powder, mixed powder all adds Mixers with Multi-direction Movement, uses swinging lozenge machine tabletting, makes plain sheet; (4) preparation of coating solution: will lubricate after fluidizer sieves and mix, and add in the alcoholic solution containing sodium carboxymethyl cellulose and propylene glycol, and use again colloid mill circular grinding after stirring by hand, and make coating solution; (5) plain sheet is joined in atresia coating pan, regulate intake, after plain sheet preheating, add above-mentioned coating solution to carry out coating; (6) by the slow releasing tablet packing making.
2. a kind of manidipine sustained release tablets as claimed in claim 1, is characterized in that lubricated fluidizer is selected from one or more in magnesium stearate, silicon dioxide, Pulvis Talci.
3. a kind of manidipine sustained release tablets as claimed in claim 1, is characterized in that sweeting agent is selected from one or more in lactose, sucrose, glucose, xylitol, sorbitol, mannitol, steviosin, saccharin sodium, aspartame.
4. a kind of manidipine sustained release tablets as claimed in claim 1, is characterized in that the plain slice prescription of manidipine sustained release tablets is as follows: Manidipine 500mg, carrageenan 200mg, magnesium stearate 50mg, citric acid 100mg, lactose 200mg; The coated formula of manidipine sustained release tablets is as follows: sodium carboxymethyl cellulose 10.5mg, propylene glycol 20mg, Pulvis Talci 9.5mg.
5. a kind of manidipine sustained release tablets as claimed in claim 1, is characterized in that the plain slice prescription of manidipine sustained release tablets is as follows: Manidipine 500mg, carrageenan 300mg, magnesium stearate 20mg, citric acid 50mg, lactose 100mg; The coated formula of manidipine sustained release tablets is as follows: sodium carboxymethyl cellulose 9.5mg, propylene glycol 19mg, Pulvis Talci 15mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210377523.9A CN102988325B (en) | 2012-10-08 | 2012-10-08 | Preparation method of manidipine sustained release tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210377523.9A CN102988325B (en) | 2012-10-08 | 2012-10-08 | Preparation method of manidipine sustained release tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102988325A CN102988325A (en) | 2013-03-27 |
| CN102988325B true CN102988325B (en) | 2014-04-02 |
Family
ID=47917757
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210377523.9A Expired - Fee Related CN102988325B (en) | 2012-10-08 | 2012-10-08 | Preparation method of manidipine sustained release tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102988325B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101468009A (en) * | 2007-12-29 | 2009-07-01 | 北京琥珀光华医药科技开发有限公司 | Method for preparing manidipine sustained release tablets and use thereof |
| CN101744760A (en) * | 2008-12-18 | 2010-06-23 | 梁颖 | Sustained release carrier for difficult soluble or easy decomposable drug |
-
2012
- 2012-10-08 CN CN201210377523.9A patent/CN102988325B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101468009A (en) * | 2007-12-29 | 2009-07-01 | 北京琥珀光华医药科技开发有限公司 | Method for preparing manidipine sustained release tablets and use thereof |
| CN101744760A (en) * | 2008-12-18 | 2010-06-23 | 梁颖 | Sustained release carrier for difficult soluble or easy decomposable drug |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102988325A (en) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120315332A1 (en) | Pharmaceutical composition including sunflower extract, preparative method and use thereof | |
| WO2013139111A1 (en) | Total flavone extract of abelmoschus manihot and preparation method thereof | |
| CN101156851A (en) | Nicardipine hydrochloride dispersion piece and method for making same | |
| CN113082166A (en) | Method for preparing health food from herba Dendrobii | |
| CN104546823B (en) | Epimedium aglucone treats or prevents the purposes in decrease of platelet disease drug in preparation | |
| WO2008145064A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
| CN102327272B (en) | Oral solid pharmaceutical composition and preparation method thereof | |
| CN106138059A (en) | A kind of stable Li Gelieting pharmaceutical composition | |
| CN102988325B (en) | Preparation method of manidipine sustained release tablet | |
| CN102716135B (en) | Lupenone prevents in preparation or treats the application in the product of diabetes | |
| CN102319225B (en) | Trimetazidine hydrochloride sustained release tablet and preparation method thereof | |
| CN108578419B (en) | A kind of hypoglycemic medicine composition of ginsenoside Rg1 and melbine | |
| CN102988323B (en) | Preparation method of aniracetam sustained-release tablet | |
| CN103860511B (en) | A kind of Pharmaceutical composition containing Irbesartan and Amlodipine Besylate Tablet and preparation method thereof | |
| CN1199650C (en) | Medicine composition of red peony total glucoside for curing cardio-cerebrovascular diseases and its preparation method | |
| CN1927301A (en) | Tongmai Jiangzhi dispersant tablet and method for making same | |
| CN109260205B (en) | Application of tetrandrine in preparation of medicine for resisting diabetes and hypertension | |
| CN103006651B (en) | Tablet containing olmesartan medoxomil and amlodipine and preparation method of tablet | |
| CN107582866B (en) | Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension | |
| CN103989752A (en) | Pharmaceutical composition used for preventing and treating diabetes mellitus combined with hypertension | |
| CN1954837A (en) | Compound herba sophorae alopecuroide active region group and its colon location preparation | |
| WO2005089441A2 (en) | Methods for increasing neurotransmitter levels using hydroxycitric acid | |
| CN101810264B (en) | Health-care food having auxiliary blood pressure reduction effect and method for preparing same | |
| CN1247203C (en) | Helicidum oral disintegation tablet and its preparing method | |
| CN103381209A (en) | Hawthorne leaf total-flavones sustained-release preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: GUANGDONG NANNING KEGUAN MEDICAL TECHNOLOGY DEVELO Free format text: FORMER OWNER: LI ZHENGMEI Effective date: 20140306 |
|
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yang Jianguo Inventor after: Liang Mengxue Inventor before: The inventor has waived the right to be mentioned |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: REQUEST NOT TO RELEASE THE NAME TO: YANG JIANGUO LIANG MENGXUE Free format text: CORRECT: ADDRESS; FROM: 211200 NANJING, JIANGSU PROVINCE TO: 530003 NANNING, GUANGXI ZHUANG AUTONOMOUS REGION |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20140306 Address after: 530003 the Guangxi Zhuang Autonomous Region high tech Zone in Nanning Kede Road No. 2 South Building Room 403 collet Applicant after: GUANGXI NANNING KEGUAN MEDICINE SCIENCE & TECHNOLOGY DEVELOPMENT CO., LTD. Address before: 211200, No. 1, Shandong Road, Lishui Economic Development Zone, Nanjing, Jiangsu Applicant before: Li Zhengmei |
|
| TA01 | Transfer of patent application right | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140402 Termination date: 20141008 |
|
| EXPY | Termination of patent right or utility model |